Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research is being presented Oct. 23 – 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to , which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with injections every three months instead of once a week."

Provided by American Association of Pharmaceutical Scientists

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Treating the aging knee as an organ

Feb 14, 2011

The human body is made up of several organs composed of tissues that enable them to perform a particular function. The heart circulates blood; the brain is the micro-neuro center of the body; the lungs bring in oxygen and ...

New method could help prevent osteoarthritis

Sep 12, 2011

A new method is set to help doctors diagnose osteoarthritis at such an early stage that it will be possible to delay the progression of the disease by many years, or maybe even stop it entirely.

HRT increases likelihood of hip and knee replacement

Oct 28, 2008

(PhysOrg.com) -- Having more children and using hormone replacement therapy (HRT) increases the likelihood that women will have joint replacement surgery, a large Oxford University-led study has shown.

Recommended for you

ACR: Most hospitalizations for gout are preventable

Nov 18, 2014

(HealthDay)—Most hospitalizations for a primary diagnosis of gout are preventable, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in ...

TNF inhibitors may increase cancer risk in the eye

Nov 17, 2014

One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.